Home › Funds › JOHNSON & JOHNSON › PTGX
JOHNSON & JOHNSON position in PTGX
PROTAGONIST THERAPEUTICS INC · Health Care
JOHNSON & JOHNSON reported holding 2,449,183 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$345.1M, representing 45.30% of its reported portfolio and ranking #1 among its reported holdings. JOHNSON & JOHNSON has disclosed PTGX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How JOHNSON & JOHNSON's PTGX position evolved
JOHNSON & JOHNSON first disclosed a stake in PTGX in Q3 2023 at 2,449,183 shares (US$40.9M). The position peaked in Q3 2026 at 2,449,183 shares, worth US$345.1M. Across 13 filings, JOHNSON & JOHNSON held the position steady without any share-count change. The most recent filing (Q3 2026) shows 2,449,183 shares valued at US$345.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.45M | $40.85M | New |
| Q4 2023 | 2.45M | $56.16M | Hold |
| Q1 2024 | 2.45M | $70.85M | Hold |
| Q2 2024 | 2.45M | $84.86M | Hold |
| Q3 2024 | 2.45M | $110.21M | Hold |
| Q4 2024 | 2.45M | $94.54M | Hold |
| Q1 2025 | 2.45M | $118.44M | Hold |
| Q2 2025 | 2.45M | $136.40M | Hold |
| Q3 2025 | 2.45M | $162.70M | Hold |
| Q4 2025 | 2.45M | $213.91M | Hold |
| Q1 2026 | 2.45M | $258.14M | Hold |
| Q2 2026 | 2.45M | $300.22M | Hold |
| Q3 2026 | 2.45M | $345.07M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PTGX and 13F data
PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 50 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PTGX
- Farallon Capital Management 6.35M sh · $778.25M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.35M sh · $778.25M · Q2 2026
- RTW INVESTMENTS, LP 5.06M sh · $620.40M · Q2 2026
- Woodline Partners LP 1.41M sh · $173.35M · Q2 2026
- PERCEPTIVE ADVISORS LLC 981.88K sh · $120.36M · Q2 2026
- ADAR1 Capital Management, LLC 960.86K sh · $117.78M · Q2 2026
- Hood River Capital Management LLC 882.74K sh · $108.21M · Q2 2026
- 683 Capital Management, LLC 290.00K sh · $35.55M · Q2 2026
- NEXTBio Capital Management LP 219.33K sh · $30.90M · Q3 2026
- Eagle Health Investments LP 248.32K sh · $30.44M · Q2 2026
More on JOHNSON & JOHNSON
FAQ
How long has JOHNSON & JOHNSON held PTGX?
JOHNSON & JOHNSON has disclosed PTGX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is JOHNSON & JOHNSON's current position in PTGX?
As of Q3 2026, JOHNSON & JOHNSON holds 2.45M shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $345.07M, representing 45.30% of its reported portfolio and ranking #1.
Has JOHNSON & JOHNSON been buying or selling PTGX?
In the latest 13F filing (Q3 2026), JOHNSON & JOHNSON held unchanged its position in PTGX. The position peaked in Q3 2026 at 2.45M shares.
Which other funds hold PTGX?
Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.